Getting in the door: who to contact to offer lab services
Operation Expand Testing (ET)
This program, administered by the US Department of Health and Human Services in partnership with the US Department of Defense, has established four coordinating hubs to provide COVID-19 testing for K-12 schools and other “congregate settings” (e.g., homeless shelters and nursing homes) in their respective regions.
Each hub is run by a different testing laboratory, which is supposed to connect schools that need testing with labs in the region that have "excess capacity" for testing. To be one of the labs that is part of the hub program in your region, get in touch with the lab coordinating the program in your area.
Includes Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Vermont, Virginia, West Virginia.
This program supplies turn key testing solutions to underserved school districts that can't stand up a testing program on their own without significant hands-on assistance.
ESSER, CRSSA, GEER and ARP
Contact: Miguel Cardona
Phone: (860) 713-6500
Connecticut Department of Education website
District of Columbia (DC)
Contact: Phyllis Unebasami
Phone: (808) 784-6161
Contact: Margie Vandeven
Contact: Ellen Essick
Phone: (701) 328-2824
Contact: David Volkman
Contact: Michaela Miller
Contact: Barbara Van Haren
Phone: (608) 266-1649
Important Regulatory Information about SalivaDirect™
SalivaDirect™has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.